Wednesday, 20 June 2018 - 13:55
  • it
  • de
  • en
  • fr

Type 1 diabetes

Sanofi seeks to restore leadership in diabetes treatments

Sanofi is trying to restore its leading position in diabetes treatments, like at the time when its insulin Lantus was among blockbusters. The France-based group is now largely focusing on sotagliflozin, which acts as a SGLT-1 and SGLT-2 inhibitor and…

Roche gains control of diabetes app with 1 million users

In an announcement made yesterday afternoon, Roche indirectly reiterated it plans to stay in the competitive and dynamic diabetes industry. Yesterday, indeed, it was made public that the Basel-based group had acquired Austria-based mySugr, whose main asset is an app…

Medtronic starts marketing artificial pancreas (type -1 diabetes).

Medtronic issued a press release announcing it will launch its “hybrid closed-loop system” artificial pancreas on the US market. The system, named MiniMed 670G, is an insulin pump approved by FDA, which ensures – through a specific algorithm, that basal…

FDA approves Medtronic’s “artificial pancreas”

FDA has approved Medtronic’s MiniMed 670G hybrid closed looped system. This is the first device approved by the US Agency that monitors glucose and allows to deliver the appropriate dose of basal insulin in patients with type-1 diabetes, 14 years…

Freestyle Libre reduces hypoglycemia in type-1 diabetes patients

Findings from a multicenter, prospective, randomized trial which has assessed the use of Freestyle Libre Flash Glucose Monitoring System (Abbott Diabetes Care) vs usual self-monitoring in 328 patients with type 1 diabetes in good glycemic control were published some days…

CHMP, green light to NovoRapid for use in children

Novo Nordisk has announced that EMA CHMP has adopted a positive opinion to extend the use of NovoRapid (insulin aspart) for children aged 1 year and over. Europe has the highest number of children with type 1 diabetes, with approximately…